Yazar "Karagol, H." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    The effect of serum ADMA levels on infarct volume and prognosis in patients with acute ischemic stroke
    (Elsevier Science Bv, 2009) Salam, F.; Celik, Y.; Karagol, H.; Balci, K.; Asil, T.
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Prognostic factors for renal cell carcinoma: Trakya University experience from Turkey
    (Wiley, 2010) Yurut-Caloglu, V.; Caloglu, M.; Kaplan, M.; Oz-Puyan, F.; Karagol, H.; Ibis, K.; Cosar-Alas, R.
    The purpose of the present study is to evaluate the prognostic factors of patients with renal cell carcinoma. The treatment results such as distant metastasis-free survival and overall survival of 59 previously untreated patients were retrospectively analysed. Median follow-up was 17.5 months (3.8-88.5 months). Overall survival was 22.4 months (3-87 months). Distant metastasis developed in 35 (59%) patients. The Eastern Cooperative Oncology Group (ECOG) performance status (P = 0.022), tumour size (P = 0.025) and lymphatic invasion (P < 0.0001) were significantly effective prognostic factors for distant metastasis-free survival on multivariate analysis. Related to overall survival, gender (P = 0.025), ECOG performance status (P = 0.027), nuclear grade (P = 0.002), tumour size (P = 0.029), T stage (P = 0.044), nodal involvement (P = 0.003), surgical margin (P = 0.046), renal sinus invasion (P < 0.0001), perineural growth (P = 0.001) and lymphatic invasion (P < 0.0001) were significant prognostic factors on univariate analysis. Gender (P = 0.008), ECOG performance status (P = 0.027), tumour size (P = 0.025) and lymphatic invasion (P < 0.0001) retained their significance on multivariate analysis. We concluded that the most important prognostic factors for patients with renal cell carcinomas are ECOG performance status, tumour size and lymphatic invasion.
  • Küçük Resim Yok
    Öğe
    Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience
    (Imprimatur Publications, 2009) Caloglu, M.; Yurut-Caloglu, V.; Karagol, H.; Bayir-Angin, G.; Turan, F. N.; Uzal, C.
    Purpose: To evaluate the survival of patients with glioblastoma multiforme (GBM) and analyse the prognostic Actors influencing survival. Patients and methods: Seventy-eight consecutive patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ) (in 21 patients) between 1999 and 2006 were retrospectively analysed. Results: Sixty-seven (85.5%) patients had undergone gross total or subtotal resection before RT The median overall survival was 9.8 months, and significantly influenced by age (p=0.02), Karnofsky performance status (p=0.001), RT (p<0.0001), gender (p=0.02), concomitant TMZ (p=0.003), RT waiting time (p=0.014), and treatment time (p=0.01) in univariate analysis. In multivariate analysis, older age (p=0.03), male gender (p=0.01), absence of concomitant TMZ (p=0.008), RT dose below 60 Gy (p=0.03), RT waiting time more than 20 days (p=0.01), and treatment time more than 76 days (p=0.0072) were poor prognosticators. Conclusion: This study emphasizes the importance of female gender, dose and duration of RT and RT waiting time in patients with glioblastoma multiforme.